Vivesto
Develops therapies for hard-to-treat cancers in human and veterinary oncology.
VIVE | ST
Overview
Corporate Details
- ISIN(s):
- SE0000722365 (+4 more)
- LEI:
- 5493003TZPR4B7QO9L49
- Country:
- Sweden
- Address:
- Box 3061, 169 03 SOLNA
- Website:
- https://www.vivesto.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Vivesto is a specialty pharmaceutical company focused on developing new treatment options for hard-to-treat cancers in areas with significant unmet medical needs. The company's portfolio includes drug candidates for both human and veterinary oncology. Its business model involves advancing projects through in-house development, strategic partnerships, and out-licensing agreements for its assets, which include products like Apealea and Paccal Vet. Formerly known as Oasmia Pharmaceutical AB, Vivesto concentrates on developing therapies for diseases with substantial market potential.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Vivesto and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-12 08:00 |
Interim Report
|
Swedish | 640.9 KB | |
| 2025-05-08 10:30 |
Post-Annual General Meeting Information
Kommuniké från årsstämma i Vivesto AB
|
Swedish | 54.9 KB | |
| 2025-05-08 10:30 |
Post-Annual General Meeting Information
Report from Annual General Meeting in Vivesto AB
|
English | 54.6 KB | |
| 2025-05-08 08:00 |
Quarterly Report
|
Swedish | 612.7 KB | |
| 2025-03-18 07:15 |
M&A Activity
Vivesto licenses Apealea to China’s Zhida Pharmaceutical
|
English | 64.5 KB | |
| 2025-03-18 07:15 |
Regulatory News Service
Vivesto utlicensierar Apealea till kinesiska Zhida Pharmaceutical
|
Swedish | 64.9 KB | |
| 2025-02-20 08:00 |
Earnings Release
|
Swedish | 935.6 KB | |
| 2024-11-21 08:00 |
Quarterly Report
|
Swedish | 3.4 MB | |
| 2024-11-07 10:54 |
M&A Activity
Vivesto signs Apealea option agreement with Zhida Pharmaceutical
|
English | 63.9 KB | |
| 2024-11-07 10:54 |
Regulatory News Service
Vivesto ingår optionsavtal för Apealea med Zhida Pharmaceutical
|
Swedish | 64.3 KB | |
| 2024-08-22 08:00 |
Interim Report
|
Swedish | 917.1 KB | |
| 2024-05-23 10:48 |
Post-Annual General Meeting Information
Report from Annual General Meeting in Vivesto AB
|
English | 55.7 KB | |
| 2024-05-23 10:48 |
Post-Annual General Meeting Information
Kommuniké från årsstämma i Vivesto AB
|
Swedish | 55.7 KB | |
| 2024-05-23 08:00 |
Quarterly Report
|
Swedish | 900.5 KB | |
| 2024-04-23 08:05 |
Annual Report
|
Swedish | 13.4 MB |
Automate Your Workflow. Get a real-time feed of all Vivesto filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Vivesto via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-08-19 | Anders Härfstrand | Other | Buy | 20,000 | 53,132.58 SEK |
| 2021-07-16 | Peter Zonabend | Other | Buy | 100,000 | 302,623.60 SEK |
| 2021-07-14 | Fredrik Järrsten | Other | Buy | 20,000 | 58,200.00 SEK |
| 2021-07-13 | Francois-Regis Martelet | Other | Buy | 41,000 | 121,370.00 SEK |
| 2021-07-08 | Birgit Agneta Stattin Norinder | Other | Buy | 35,000 | 104,480.00 SEK |
| 2021-07-06 | Anders Härfstrand | Other | Buy | 100,000 | 285,653.00 SEK |
| 2020-10-13 | Francois-Regis Martelet | Other | Buy | 20,000 | 85,000.00 SEK |
| 2020-10-12 | Anders Härfstrand | Other | Buy | 30,000 | 130,800.00 SEK |
| 2020-06-18 | Sven Rohmann | Other | Sell | 100,000 | 620,638.00 SEK |
| 2020-06-18 | Sven Rohmann | Other | Sell | 78,370 | 504,702.80 SEK |
